These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11697040)

  • 1. Quantitative structure-activity relationship of some HIV-1 protease inhibitors: a Fujita-Ban type analysis.
    Mekapati SB; Sivakumar R; Gupta SP
    J Enzyme Inhib; 2001; 16(3):185-97. PubMed ID: 11697040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
    Kempf DJ; Sham HL; Marsh KC; Flentge CA; Betebenner D; Green BE; McDonald E; Vasavanonda S; Saldivar A; Wideburg NE; Kati WM; Ruiz L; Zhao C; Fino L; Patterson J; Molla A; Plattner JJ; Norbeck DW
    J Med Chem; 1998 Feb; 41(4):602-17. PubMed ID: 9484509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
    Li D; Liu MS; Ji B; Hwang KC; Huang Y
    Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors.
    Saranya N; Selvaraj S
    Curr Comput Aided Drug Des; 2012 Mar; 8(1):10-49. PubMed ID: 21999608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.
    Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K
    Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
    Ghosh AK; Osswald HL; Prato G
    J Med Chem; 2016 Jun; 59(11):5172-208. PubMed ID: 26799988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors.
    Yusa K; Song W; Bartelmann M; Harada S
    J Virol; 2002 Mar; 76(6):3031-7. PubMed ID: 11861869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
    Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
    Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
    Halder AK; Jha T
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].
    Soler-Palacín P; Fàbrega A; María López R; Figueras C
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645
    [No Abstract]   [Full Text] [Related]  

  • 16. MIA-QSAR modeling of the anti-HIV-1 protease activities and cytotoxicities of ritonavir analogs.
    Silva DG; Freitas MP
    Curr Drug Saf; 2012 Sep; 7(4):269-81. PubMed ID: 23062239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.
    Mimoto T; Terashima K; Nojima S; Takaku H; Nakayama M; Shintani M; Yamaoka T; Hayashi H
    Bioorg Med Chem; 2004 Jan; 12(1):281-93. PubMed ID: 14697794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
    Kempf DJ
    Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.